Piper Sandler analyst maintains an Overweight rating on Teva, citing positive feedback on duvakitug's potential in treating ...

Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

Barclays analyst Balaji Prasad maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) today and set a price target of $28.00.

The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries Ltd (NYSE:TEVA) is preparing for its latest quarterly earnings report, due ...

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) is expected to be announcing its earnings results before the market opens on Wednesday, January 29th. Analysts expect the company to ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

The Delaware Supreme Court affirmed Friday a trial court’s decision in favor of Teva Pharmaceutical Industries Ltd.'s US unit ...

Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) had its price target raised by UBS Group from $28.00 to $30.00 in a research note published on Thursday,Benzinga reports. UBS Group currently ...

Teva Pharmaceutical Industries (NYSE:TEVA), a global leader in generic and specialty medicines with a market capitalization of $24.6 billion, has been navigating a complex landscape of legal ...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva ...

1 Day TEVA -0.50% DJIA -0.32% S&P 500 -0.29% Health Care/Life Sciences -0.52% ...